Current projects

We encourage prospective D/P's (donor/participants) to become involved in current and future studies. If a study listed does not apply to your particular situation we still invite you to register so that we may include you in our database and contact you for future studies.

We are looking for D/P's in the following categories:

ID # Required D/P's Enrolled D/P's Remaining D/P's Inclusion Criteria
235480 19 20 -1 Pre-Selected Chlamydia Positive Samples from Inventory (Serum and Plasma)
235406 300 74 226 SARS-CoV-2 RNA Hologic Testing (Felix Chao and Peter Kim)
235321 1 0 1 Fresh Whole Blood from Healthy Donor(s)
235306 6 6 0 Pre-Selected HxV Negative Samples from Inventory
235301 6 5 1 Pre-Selected HIV Samples from Inventory with Viral Load and Specific Mutation
235121 15 15 0 Double Spun Plasma from Healthy (HxV Negative) D/Ps - INC4581474/ SACQ_0002410
235115 24 0 24 Female Vaginal Sample Collection Protocol for Panel Development
234803 200 0 200 Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, Q_16976)
234476 3 6 -3 Prospective SARS-CoV-2 Negative Raw Saliva Samples - OR21-265
234348 5 5 0 Pre-Selected HIV Samples from Inventory with Viral Load
234347 5 5 0 Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load
234090 17 33 -16 Pre-Selected anti-HBs Positive Samples from Inventory
234079 240 30 210 Prospective Whole Blood Collection from HxV Negative D/Ps
233572 1000 2542 -1542 Disposition of BioRepository Samples - Negatives Covid Swabs
233409 12 4 8 Pre-Selected HCV Positive Samples form Inventory (K2EDTA and/or Citrate Plasma)
233408 12 14 -2 Pre-Selected HBV Positive Samples form Inventory
233218 150 8 142 IDS-21MAXCOMBO - SARS-CoV-2 Hologic Aptima Testing
233007 1000 27 973 CBC Initiative, SACQ_0002392 (INC4932295) - SRF_0002617 - Buffy Coat - BCW
232963 8 8 0 Buffy Coat from Healthy D/Ps with Specific WBC Count - INC4932295
232619 8 8 0 HIV Positive Stability Study
231875 5 5 0 Fresh Whole Blood from Healthy (HxV Negative) D/Ps - INC4687934_2
231769 10 11 -1 Pre-screening protocol (HIV Viral Load)Samples to be tested in Abbott for Raquel (Cepheid) request
231541 14 14 0 SARS-CoV-2 Fresh Negative Nasopharyngeal Swabs and Nasal Swabs (Copan & Remel) - OR21-247
231203 50 0 50 Vaginal Swab Samples From Subjects With Suspected STIs - Clinical Protocol TP-000033
231202 50 53 -3 Beta Study of the Visby Sexual Health Test - Clinical Protocol TP-000516
230582 1000 593 407 Disposition of BioRepository Samples - Lav/Yellow Tubes
230530 20000 1295 18705 Customer Samples kept in Biorepository (CMVG Samples, Susan Rimpel)
230296 1 1 0 WBC of 8000 to 10000 cells/ul or higher
230007 30 30 0 Prospective SARS-CoV-2 Negative Raw Saliva Samples - OR21-232
229502 400 402 -2 SARS-CoV-2 Fresh Negative Saliva Samples in 2 collection devices (SpeciMAX and Spectrum) + Raw Saliva Sample
228847 1 1 0 Pre-Selected HBV Samples from Inventory with Viral Load and Genotype
228548 100 102 -2 Remnant VZV Samples (IGG Negative)
228201 20000 466 19534 Customer Samples kept in Biorepository from Minneapolis Medical Research Foundation (MMRF)
227994 130 5 125 PAS-19SUST054 - HCV
227993 130 1 129 PAS-19SUST052 - HBV
227992 130 10 120 PAS-18SUST041 - Evaluation of the BD Vacutainer® K2EDTA Blood Collection Tubes with Hemogard™ Closure using Molecular Diagnostic Testing for HIV-1 Viral Load (VL) Assay
227629 50 8 42 SARS-CoV-2 Positive NP and Saliva Matched Set
227621 3 2 1 HIV-1 Positive Prospective Blood Collection Protocol:
- Three (3) D/Ps to have an HIV-1 Viral Load of:
Donor #1: 1000 copies/mL (+/- 10%)
Donor #2: 2000 copies/mL (+/- 10%)
Donor #3: 3000 copies/mL (+/- 10%)
227020 8 8 0 Pre-Selected HIV Subtyped Samples from Inventory
226510 300 299 1 SARS-CoV-2 Fresh Negative Saliva Samples in 3 collection devices (Isohelix, SpeciMAX and Spectrum) + Raw Saliva Sample
226001 100 37 63 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
225611 10000 0 10000 A Multi Site, Longitudinal, Prospective Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
225101 1000 1 999 COVID-19 Testing; Private Office
224701 360 0 360 cX8-COV-549: Classic Repro Protocol
224534 180 124 56 SARS-CoV-2 Negative NP and Raw Saliva Matched Set
224514 600 76 524 Initiative to Screen Potential Study Candidates (SUST)
223768 12 12 0 Remnant SARS-CoV-2 Positive Dry Nasal Swabs
222843 20 0 20 Remnant SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
222391 3 0 3 Prospective Whole Blood Collection from HxV Negative D/Ps
222390 6 6 0 Prospective Whole Blood Collection from HxV Negative D/Ps
221566 200 200 0 SARS-CoV-2 Fresh Negative Saliva Samples in collection devices (SpeciMAX and Spectrum) + NP swab remnant
220541 100 42 58 Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, Q_16913)
219607 1000 9 991 COVID-19 Testing; Private Office
219219 22 21 1 Normal Serum and Plasma Samples for Panels_Q_16894, Q_16914 and Q_16913
218357 325 473 -148 Prospective Healthy Subject Blood Collection Protocol
217882 65 12 53 Prospective SARS-CoV-2 Positive Sample Collection Protocol (NPS and Saliva)
213622 2500 0 2500 Protocol: cX8-CAB-547 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
210687 7 8 -1 Pre-Selected HCV Positive Samples from Inventory with HCV Viral Load and Genotype
210071 2500 339 2161 Protocol: cX8-CAB-533 - cobas® SARS-CoV-2 & Influenza A/B for Use on the cobas® 6800/8800 Systems: A Method Comparison Study
208168 1000 111 889 COVID-19 Testing; Private Office
206253 60 20 40 High Volume K2EDTA Whole Blood and Plasma from Healthy Donors
205506 200 0 200 Urine and Saliva Matched Set from Healthy D/Ps
-100 subject collected in the morning until 9 AM
-100 subjects collected in the afternoon after 4 PM
205083 10 0 10 Prospective Urine Collection from Healthy Donors
204811 150 190 -40 SARS-CoV-2 Negative Raw Saliva Samples from Inventory
204810 40 0 40 Prospective SARS-CoV-2 Negative Raw Saliva Samples
Ship same day
204808 50 0 50 SARS-CoV-2 Negative Nasal Swabs from Inventory
203243 2000 0 2000 Pre-Selected HxV Negative Samples from Inventory
202732 1000 99 901 PROTOCOL 274C3 - Clinical Evaluation of the Xpert® Xpress CoV-2/Flu/RSV XC Test on the GeneXpert Dx and Infinity Systems in Laboratory and Near-Patient Testing Environment
201758 130 44 86 PAS-18SUST033 - Validation of the Clinical Performance of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure in Comparison with the Greiner Vacuette® K2EDTA Gel Tubes for Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
200508 1000 60 940 COVID-19 Testing; Private Office
198619 2 2 0 HIV Viral Load Testing
198618 1 1 0 HCV Viral Load Testing
198399 220 127 93 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
198391 500 0 500 Prospective Healthy Subject Blood Collection Protocol
197511 20 0 20 SARS-CoV-2 Positive Serum and NPS Matched Set Samples from Inventory
195801 220 0 220 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
195775 20000 1380 18620 Customer Samples kept in Biorepository from HBcT2 [JRID#93116]
195561 50 104 -54 SARS-CoV-2 RNA Hologic Testing
195554 200 328 -128 SARS-CoV-2 RNA Hologic Testing
194268 150 0 150 Prospective Nasal Swab Collection Protocol
194052 21 0 21 HxV Negative K2EDTA Plasma from Inventory - SRF_TBA
193266 200 130 70 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps
191880 875 600 275 Prospective Healthy Subject Blood Collection Protocol
190737 5000 9 4991 SARS-CoV-2 Survey (PT)
184026 700 542 158 SARS-CoV-2 RNA Hologic Testing
182696 1000 355 645 Protocol: COL-RESP-528 - Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections
180141 15 15 0 Normal Serum and Plasma Samples for Panels_Q_16847
179314 5 586 -581 Pre-Selected HBV Samples from Inventory with Viral Load
178076 130 79 51 PAS -19SUST046 - Evaluation of BD Vacutainer® PPT™ Plasma Preparation Tube with Hemogard™ Closure for Repeatability and Reproducibility of Molecular Diagnostic Testing using HIV-1 Viral Load (VL) Assay
176622 10 0 10 Normal Serum Samples with Unit Back-Ups
DP willing to donate a Whole Blood Unit
176111 25 0 25 Prospective SARS-CoV-2 Collection from Symptomatic D/Ps - SRF_6026_Q16802
175884 500 97 403 SARS-CoV-2 RNA Hologic Testing
175792 10000 116 9884 COVID-19 Testing; Tu Cara me Sue
175398 10000 552 9448 COVID-19 Testing; Crew-Royal Caribbean Cruises Ltd
175121 1000 27 973 CBC Initiative
174026 1000 122 878 COVID-19 Testing; Private Office
173505 20 20 0 SARS-CoV-2 Positive Nasopharyngeal Swabs from Inventory
172886 1000 1018 -18 COVID-19 Testing; Private Office
169711 400 398 2 SARS-CoV-2, Nasal swab, Nasopharyngeal Swab, Oropharyngeal swab and Saliva
169440 300 110 190 Remnant Pregnancy Samples
169439 100 258 -158 Remnant HSV Samples
168884 50 0 50 Evaluation of the prognostic performance of HostDx ViralSeverity to predict outcomes of SARS-CoV-2
168867 1000 310 690 COVID-19 Testing; Private Office
168264 10 10 0 SARS-CoV-2 Negative Nasal, Nasopharyngeal Swab
168078 50 2 48 Prospective COVID-19 Positive Sample Collection Protocol (NPS and Raw Saliva)
165868 1000 114 886 COVID-19 Testing; Private Office
164218 1000 404 596 COVID-19 Testing; Private Office
163904 1000 871 129 COVID-19 Testing; Private Office
162422 1000 75 925 COVID-19 Testing; Private Office
162417 35 34 1 Fresh Whole Blood from Healthy (HxV Negative) D/Ps - SRF_5868_4
161853 100 861 -761 Abbott RealTime CT/NG Testing, Cepheid_248C1& 248C3
160615 47 47 0 Clinical Performance of the Checkable Medical COVID-19 At-home Rapid Antibody Test and the Clarity COVIBLOCK COVID-19 IgG/IgM Antibody Test (Positive)
160614 75 90 -15 Clinical Performance of the Checkable Medical COVID-19 At-home Rapid Antibody Test and the Clarity COVIBLOCK COVID-19 IgG/IgM Antibody Test (Negative)
157934 1000 803 197 COVID-19 Testing; Private Office
156661 10000 1690 8310 COVID-19 Testing; Private Office
155679 30 310 -280 SARS-CoV-2 Positive Nasal, Oropharyngeal Dry Swab and Raw Saliva Collection Protocol
154904 10000 40 9960 COVID-19 Testing; Private Office
154536 1000 458 542 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 500 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
153900 10000 31303 -21303 COVID-19 Testing, Florida Department of Health
152854 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
152825 5000 102044 -97044 COVID-19 Testing
152764 9 27 -18 HCV Viral Load Testing
152672 5000 40 4960 Follow-UP_COVID-19 Testing_Blood and Nasopharyngeal Swabs
152661 1000 41 959 Collection protocol for Panel construction (Custom HIV-1 Matched sets panels, QT00016682)
152645 24 0 24 Female Vaginal Sample Collection Protocol for Panel Development
152331 5000 1654 3346 COVID-19 Testing
151990 195 13 182 Pre-Selected CMV Positive Samples form Inventory (SRF_5628 - STING Project)
151989 195 50 145 Pre-Selected CMV Negative Samples form Inventory (SRF_5628 - STING Project)
151893 500 282 218 Fresh Whole Blood, Capillary blood, Nasopharyngeal swab and Nasal swab match set from symptomatic individuals
151886 500 285 215 Fresh Whole Blood, Capillary blood, Nasopharyngeal swab and Nasal swab match set from symptomatic individuals
151681 5000 3 4997 Refer to Processing Instructions @ Attachment Tab
151476 1 0 1 HIV Group and Subtype Testing
150014 500 64 436 Seegene Validation Collection Protocol from Male and Female Samples
149547 5000 180 4820 Refer to Processing Instructions @ Attachment Tab
TESTS TO SELECT PER LOCATION - REFER TO ATTACHMENT TAB
149472 100 69 31 HIV-2 Prospective Blood Collection Protocol - SRF_5628
149267 200 135 65 Prospective Nasopharyngeal Swab Collection- SRF_5469
148791 5000 24 4976 Refer to Processing Instructions @ Attachment Tab
146391 92 0 92 High Volume Whole Blood Collection to Evaluate The Long-Term Stability of Roche cfDNA tubes - SRF_5743
146000 520 282 238 Prospective Nasal and Nasopharyngeal Matched Swab Sample Collection Protocol
145574 5000 60 4940 Refer to Processing Instructions @ Attachment Tab
144888 195 1277 -1082 Pre-Selected Negative Samples form Inventory (SRF_5628 - STING Project (SRF_0002000))
144620 5000 29 4971 Refer to Processing Instructions @ Attachment Tab
144001 100 825 -725 Pediatric EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM):
- 50 samples from subjects with the ages of 2 through 12 years of age AND
- 50 samples from subjects with the ages of 13 through 21 years of age
- Gender: Male or Female
- Minimum Volume: 1.5 mL (1.2 mL's)
- Storage Temperature: Samples must have been frozen at -20°C or below within 2 days of collection.
143401 1500 1158 342 Cerebral Spinal Fluid (CSF) Unit from Live D/Ps
- Minimum total volume of 3000 ml required
- Individual samples of at least 0.25 ml
- The samples must have no trace of hemolysis (red color).
- Stored under -80°C.
- Remnant material acceptable
- No IRB nor Informed Consent needed
- No clinical history
- Custom Manifest file
142755 5000 60 4940 Refer to Processing Instructions @ Attachment Tab
141914 1000 7 993 HIV Initiative
141834 1500 1246 254 HIV-1 Viral Load Testing Proposal
141493 5000 30 4970 HCV Viral Load and Genotype Survey (PT)
141491 5000 12 4988 HBV Viral Load Survey (PT)
141490 5000 30 4970 HIV Viral Load Survey (PT)
141142 50 12 38 Fresh Whole Blood from Healthy (HxV Negative) D/Ps - SRF_5635
140923 5000 50 4950 Refer to Processing Instructions @ Attachment Tab
140922 5000 30 4970 Refer to Processing Instructions @ Attachment Tab
140530 5000 10 4990 Rubella IgG (AAB - PT)
140528 5000 6 4994 ToRCH (AAB - PT)
140300 1500 1500 0 HIV-1 Viral Load Testing Proposal
139409 5000 65 4935 Pregnancy (PT)
137933 5000 0 5000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
137683 930 235 695 Preeclampsia Blood Collection Protocol from Asymptomatic and Symptomatic Populations
136025 300 357 -57 EBV Samples (Tested for EBV Early Ag, EBV Nuclear Ag, EBV VCA IgG and EBV IgM)
135041 100 0 100 GC/CT/MG/TV prospective collection at Budapest
134700 60 25 35 Abbott Real Time EBV and BKV Testing - SRF_5465
134182 100 80 20 HBV/Mayaro Samples from Colombia
133225 200 274 -74 Prospective HCV Positive serum collection
129688 200 123 77 EBV / EBK Samples from National Center of Urology - Tbilisi, Georgia
129538 1000 309 691 RPR Initiative
128402 1000 64 936 CBC Initiative
124266 5000 143 4857 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cote D'Ivoire
122931 5000 1510 3490 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
122654 5000 171 4829 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Swaziland
120851 140 26 114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
120409 300 84 216 Matched Prospective Collection Protocol from an HCV, HBsAg and/or RPR Positive Reactive Population
109382 100 32 68 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
109381 300 6 294 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
108692 1000 939 61 HxV Testing Initiative
102772 50 26 24 Random Cadaveric Samples
102419 1000 445 555 Samples on hold for future shipments to China
98830 10000 0 10000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP, Endocervical Swab, Vaginal Swab, Nasal Swab, Pharyngeal Swab, Rectal Swab, Urethral Swab and/or Urine Samples
98084 1000 562 438 CBC Qualifying Job Request
96278 5000 185 4815 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
96055 40 1628 -1588 Hologic Panels for HIV and HCV
94841 500 1 499 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV - LGR
93116 700 734 -34 Prospective Blood Collection Protocol from D/Ps with Signs & Symptoms or at High Risk for Hepatitis
80997 5000 428 4572 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV from Cameroon
79734 100 0 100 Prospective Zika Screening and Longitudinal Sample Collection Protocol
78138 300 140 160 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HCV
78137 300 414 -114 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV
74261 10000 0 10000 A Recurrent Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from D/Ps that have been Diagnosed or Suspected to have HIV, HBV, HCV, Syphilis, CMV, Toxo and/or Rubella
68258 10000 0 10000 A Multi Site, Longitudinal, Prospective Blood Collection Protocol in order to obtain Samples from Normal Healthy D/Ps
66495 200 225 -25 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World for Dengue
63869 1 2 -1 Negative Material for Panel Member
63868 1000 555 445 Blinded HIV/HBV/HCV Prospective Blood Collection Protocol from Guinea Bissau
56717 20000 0 20000 A Multi-Site, Multi-Point, Prospective Collection Protocol in order to obtain PAP , Endocervical, Vaginal, Nasal and/or Urine Samples
55075 10000 28 9972 Beta HCG Matched Set Prospective Blood Collection Protocol
54664 200 148 52 Random Cadaveric Samples
38626 300 143 157 Prospective Sample Collection of Specifically Diagnosed D/Ps with Diseases of the Liver or Related Complications:
·50 x Alcoholic liver disease
·30 x Autoimmune hepatitis
·30 x Fatty liver disease
·30 x Non-alcoholic Steatohepatitis (NASH)
·30 x Primary Biliary Cirrhosis (PBC)
27615 15000 633 14367 Prospective Blood Collection Protocol in order to Collect Samples from Donor/Participants (D/Ps) in Low Socio-Economic Regions of the World
26761 10000 482 9518 HIV Positive Time Stability Whole Blood Collection Protocol
10694 3000 2234 766 HCV Longitudinal Prospective Blood Collection Protocol
10693 3000 369 2631 HBV Multi-Point Prospective Blood Collection Protocol
8568 300 1528 -1228 Positive Plasma Units from Blood Centers Around the World (HIV, HBsAg & HCV)



BCW helps clinicians during their research process through collection sites and D/P availability. Our collection sites have been duly inspected and adhere to our Good Manufacturing Practices thus ensuring reliability during the collection process. In addition to this we provide training seminars as part of our Quality Assurance in order to maintain the level of quality that our customers are accustomed to.

You will be invited to participate in research studies for the advancement of diagnostic technologies. Participation in these studies is voluntary. Our D/P's are informed of what the research projects are about and are given an Informed Consent, which evidences their willingness to participate. In order to protect our D/P's we never divulge your identity to the research facilities thus guaranteeing D/P confidentiality.



Contact us to learn more